



Strong interest in WorkBeads™ affimAb Edge: Next-Generation Protein A Resin for Antibody Purification

Bio-Works Technologies AB announced on August 19th, 2025, the launch of **WorkBeads™ affimAb Edge**, a resin with market leading performance designed for efficient purification of monoclonal antibodies and Fc-containing fragments or fusion proteins from laboratory to production scale.

Built on an improved macroporous agarose-based matrix and coupled with an alkali-stable recombinant Protein A ligand, **WorkBeads affimAb Edge** delivers:

- **High performance and process economy:** Dynamic binding capacities exceeding 70 mg/mL at 6 minutes residence time.
- **Superior pressure flow properties:** Enabling faster cycle times and robust process scalability.
- **Alkali stability:** Supporting repeated cleaning and sanitization with 0.5 M NaOH for extended resin lifetime.
- **Improved purity:** Demonstrated effective removal of host cell proteins (HCP) with consistently low impurity levels across 150+ cycles.
- **Low ligand leakage:** Comparable to leading resins on the market, ensuring reliable downstream results.

For the customer this means high productivity and scalability - delivering consistently high purity and yield.

The resin is available in bulk and a wide range of convenient prepacked GoBio™ column formats—from small-scale screening to production-scale purification—making it an attractive solution for both process development and commercial manufacturing.

Strong Market Response

Since its introduction, **WorkBeads affimAb Edge has already attracted significant attention from the global biopharmaceutical community**, with many large biopharma companies actively requesting samples for evaluation. This reflects the industry's need for cost-effective and high-performing alternatives in antibody purification workflows.

"WorkBeads affimAb Edge represents an important step forward in delivering performance, robustness, and process economy to our customers in biopharma. We are proud to see strong demand from leading global companies so early after launch, which reinforces the market's confidence in our technology," said Lone Carlbom, CEO, Bio-Works Technologies AB.

Contact

For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, email: lone.carlbom@bio-works.com (lone.carlbom@bio-works.com), phone: +46(0)8-502 705 84.

About Bio-Works

Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.